Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Bayer HealthCare's Eylea (aflibercept, solution for intravitreal injection) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). In ...
The European Commission has approved Regeneron Pharmaceuticals's Eylea (aflibercept) injection for the treatment of visual impairment caused by macular edema secondary to central retinal vein occlusion (CRVO). Eylea is a recombinant ...
Tags: fusion protein, Eylea
Sanofi and Regeneron Pharmaceuticals have announced the commencement of patient enrollment in two Phase 3 rheumatoid arthritis (RA) trials, the COMPARE and ASCERTAIN trials, with Sarilumab. The first fully human monoclonal antibody ...
Regeneron Pharmaceuticals and Bayer HealthCare have started a new Phase 3 VEGF Trap-Eye In Vision Impairment Due to DME (VIVID EAST-DME) trial of its Eylea (aflibercept) injection. Eylea, which is formulated as an iso-osmotic solution for ...
IBM will launch before midyear several new and improved collaboration and communication products, including a new suite for human resources tasks and a major upgrade of its Connections enterprise social networking product. The company, ...
Regeneron Pharmaceuticals has received Japanese Ministry of Health,Labour and Welfare(MHLW)approval for its Eylea(aflibercept)injection to treat patients with neovascular age-related macular degeneration(wet AMD)symptoms. Regeneron chief ...
Tags: Regeneron Pharmaceuticals, Eylea Injection, wet AMD, George Yancopoulos
Sanofi and Regeneron Pharmaceuticals have received FDA priority review for the biologics license application (BLA) of ZALTRAP (aflibercept) as a treatment for metastatic colorectal cancer (mCRC). The filing was based on the Phase III ...